NASDAQ:ASRT

Assertio Therapeutics Stock Insider Trading

Healthcare > Drug Manufacturers - Specialty & Generic

Buy ASRT

*Your capital is at risk

$23.50

+0 (+0%)

At Close: Jun 23, 2026

Assertio Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 4.05. In total, the insiders bought 2.62M and sold 846.21K ASRT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	4.05
● Buy	2.62M shares
● Sell	846.21K shares
43% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence Jun 16, 2026 Analysis Breakdown: Weakened by a contradictory positive Insider Power Score. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 16, 2026 Sell	Stock Option (Right to Buy) D-Return	Stark David Matthew Director	Director	5 415 Value: $82.0K
Jun 16, 2026 Sell	Common Stock U-Tender	Stark David Matthew Director	Director	11 420 Value: $0
Jun 16, 2026 Sell	Stock Option (Right to Buy) D-Return	Mason Heather L Director	Director	5 415 Value: $50.1K
Jun 16, 2026 Sell	Stock Option (Right to Buy) D-Return	Mason Heather L Director	Director	36 666 Value: $627.0K
Jun 16, 2026 Sell	Common Stock U-Tender	Mason Heather L Director	Director	6 666 Value: $0
Jun 16, 2026 Sell	Stock Option (Right to Buy) D-Return	Reisenauer Mark L CEO	CEO / President	26 667 Value: $313.9K
Jun 16, 2026 Sell	Stock Option (Right to Buy) D-Return	Reisenauer Mark L CEO	CEO / President	66 666 Value: $824.8K
Jun 16, 2026 Sell	Stock Option (Right to Buy) D-Return	Reisenauer Mark L CEO	CEO / President	5 415 Value: $69.0K
Jun 16, 2026 Sell	Restricted Stock Units D-Return	Reisenauer Mark L CEO	CEO / President	33 333 Value: $0
Jun 16, 2026 Sell	Common Stock U-Tender	Reisenauer Mark L CEO	CEO / President	3 583 Value: $0
Jun 16, 2026 Sell	Stock Option (Right to Buy) D-Return	Kirk Sigurd Director	Director	5 415 Value: $50.1K
Jun 16, 2026 Sell	Stock Option (Right to Buy) D-Return	Kirk Sigurd Director	Director	5 415 Value: $82.0K
Jun 16, 2026 Sell	Stock Option (Right to Buy) D-Return	Kirk Sigurd Director	Director	7 913 Value: $135.3K
Jun 16, 2026 Sell	Common Stock U-Tender	Kirk Sigurd Director	Director	12 017 Value: $0
Jun 16, 2026 Sell	Stock Option (Right to Buy) D-Return	Schlessinger Sam EVP, General Counsel	Officer	21 128 Value: $248.7K
Jun 16, 2026 Sell	Stock Option (Right to Buy) D-Return	Schlessinger Sam EVP, General Counsel	Officer	12 591 Value: $153.3K
Jun 16, 2026 Sell	Stock Option (Right to Buy) D-Return	Schlessinger Sam EVP, General Counsel	Officer	18 900 Value: $224.8K
Jun 16, 2026 Sell	Stock Option (Right to Buy) D-Return	Schlessinger Sam EVP, General Counsel	Officer	15 666 Value: $307.8K
Jun 16, 2026 Sell	Restricted Stock Units D-Return	Schlessinger Sam EVP, General Counsel	Officer	25 748 Value: $0
Jun 16, 2026 Sell	Common Stock U-Tender	Mckee William Director	Director	27 936 Value: $0
Jun 16, 2026 Sell	Stock Option (Right to Buy) D-Return	Mckee William Director	Director	5 415 Value: $82.0K
Jun 16, 2026 Sell	Stock Option (Right to Buy) D-Return	Mckee William Director	Director	5 415 Value: $50.1K
Jun 16, 2026 Sell	Common Stock U-Tender	Schlessinger Sam EVP, General Counsel	Officer	14 738 Value: $0
Jun 16, 2026 Sell	Common Stock U-Tender	Emany Sravan Kumar Director	Director	23 855 Value: $0
Jun 16, 2026 Sell	Stock Option (Right to Buy) D-Return	Emany Sravan Kumar Director	Director	1 753 Value: $28.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ASSERTIO THERAPEUTICS INC.

Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, ...

Read Full Profile Here